Manidipine Zentiva

Manidipine Dihydrochloride, the active ingredient in Manidipine Zentiva, is a calcium channel blocker presented as an oral tablet for systemic use. It selectively relaxes vascular smooth muscle, lowering blood pressure in adult patients diagnosed with hypertension. The medication is formulated for once‑daily administration under medical supervision.

GNH USA supplies Manidipine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels. Our quality‑assured supply chain adheres to EU GMP standards and supports timely delivery across multiple regions.

Manidipine Zentiva is a calcium channel blocker indicated for the management of arterial hypertension. Hypertension: reduces systolic and diastolic blood pressure in adult patients with essential hypertension.

Adverse reactions may occur with any antihypertensive therapy and should be monitored by the prescribing clinician.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, typically resolves with continued use. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness: especially after initial dosing. - Nausea: mild gastrointestinal discomfort. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence, particularly in patients with pre‑existing coronary disease. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat, potentially airway‑compromising. - Cardiac arrhythmias: uncommon but serious rhythm disturbances.

Before initiating therapy, clinicians should assess individual risk factors and monitor response. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Hepatic impairment: use with caution, adjust dose if necessary. - Elderly patients: start at lower dose and monitor for orthostatic symptoms. - Concomitant antihypertensives: evaluate for additive hypotensive effect. - Contraindication in severe hypotension or cardiogenic shock: avoid use. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Manidipine may interact with other medicines that affect blood pressure or drug metabolism. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive hypotension. - Grapefruit juice: can elevate drug levels, leading to enhanced effects. Moderate Interactions (Monitor Closely): - Diuretics: may cause electrolyte imbalances, requiring monitoring. - Beta‑blockers: combined effect on heart rate and blood pressure. - NSAIDs: may attenuate antihypertensive response. - Calcium supplements: possible reduction in drug absorption. - Alcohol: can potentiate hypotensive effects.